Kalikar Mrunalini V, Dakhale Ganesh N, Sinha Vishakha V, Giradkar Akhil B
Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India.
Department of Pharmacology, All India Institute of Medical Sciences, Nagpur, Maharashtra, India.
Perspect Clin Res. 2022 Jul-Sep;13(3):151-154. doi: 10.4103/picr.PICR_124_20. Epub 2021 Mar 26.
Very few studies conducted in India have analyzed insurance policies and clinical trial agreement (CTA) submitted to ethics committee (EC). This study was conducted to review and find out deficiencies in it.
This was a retrospective observational study. All the protocols for regulatory clinical trials and academic research sponsored by the Indian Council of Medical Research or other funding agency were included. Insurance documents and CTA submitted with the study protocols were analyzed.
A total of seventy CTA and insurance policies were analyzed. CTA mentioned that parties involved in 60 (86%) forms, scope of the agreement in 15 (21%) forms, responsibilities of the party in 68 (97%) forms, and payment details in 58 (83%) forms. Nearly 88.5% of the insurance policies mentioned whether the policy covers the participants for injury due to all clauses and 91% of the policies mentioned the validity period of insurance.
It was found that both the documents contained almost all the required elements. This was probably because this institutional EC insisted on and thoroughly reviewed the documents to ensure that adequate compensation of research-related injuries has been provided for and this fact is informed to the trial subject. As very few studies are available in the literature, we could not compare majority of the findings of this study with others.
在印度开展的研究中,极少有对提交给伦理委员会(EC)的保险政策和临床试验协议(CTA)进行分析的。本研究旨在对此进行审查并找出其中的不足之处。
这是一项回顾性观察研究。纳入了由印度医学研究理事会或其他资助机构赞助的所有监管临床试验和学术研究的方案。对随研究方案提交的保险文件和CTA进行了分析。
共分析了70份CTA和保险政策。CTA中提及参与方的有60份(86%),协议范围的有15份(21%),参与方责任的有68份(97%),支付细节的有58份(83%)。近88.5%的保险政策提及该政策是否涵盖所有条款导致的参与者伤害,91%的政策提及了保险有效期。
发现这两份文件几乎包含了所有必需的要素。这可能是因为该机构伦理委员会坚持并彻底审查了这些文件,以确保为与研究相关的伤害提供了充分补偿,并将这一情况告知试验对象。由于文献中相关研究极少,我们无法将本研究的大部分结果与其他研究进行比较。